6-Phosphogluconate dehydrogenase inhibition arrests growth and induces apoptosis in gastric cancer via AMPK activation and oxidative stress
Open Access
- 1 January 2023
- journal article
- research article
- Published by Walter de Gruyter GmbH in Open Life Sciences
- Vol. 18 (1) , 20220514
Abstract
Poor outcomes in advanced gastric cancer necessitate alternative therapeutic strategies. 6-Phosphogluconate dehydrogenase (6-PGDH), an enzyme that catalyzes the decarboxylation step in the oxidative pentose phosphate pathway, has been identified as a promising therapeutic target in many cancers. In this study, we systematically investigated the expression and function of 6-PGDH in gastric cancer. We found that 6-PGDH expression and activity were aberrantly elevated in gastric cancer tissues compared to their adjacent normal tissues. 6-PGDH knockdown using two independent shRNAs resulted in minimal 6-PGDH levels and activity, decreased growth, and enhanced gastric cancer cell sensitivity to 5-flurorouracil. However, 6-PGDH knockdown did not affect the cancer cells. Mechanistic studies showed that 6-PGDH inhibition disrupted lipid biosynthesis and redox homeostasis in gastric cancer, inhibited growth, and induced apoptosis. Notably, the in vitro findings were validated using an in vivo gastric cancer xenograft mouse model. This study established that 6-PGDH is broadly elevated in gastric cancer patients and that 6-PGDH inhibition can sensitize gastric cancer cells in response to chemotherapy.Keywords
This publication has 33 references indexed in Scilit:
- Anti-inflammatory and anti-hyperalgesic effects of milnacipran in inflamed rats: involvement of myeloperoxidase activity, cytokines and oxidative/nitrosative stressInflammopharmacology, 2020
- Tyrosine phosphorylation activates 6-phosphogluconate dehydrogenase and promotes tumor growth and radiation resistanceNature Communications, 2019
- 6PGD inhibition sensitizes hepatocellular carcinoma to chemotherapy via AMPK activation and metabolic reprogrammingBiomedicine & Pharmacotherapy, 2019
- Inhibiting 6-phosphogluconate dehydrogenase enhances chemotherapy efficacy in cervical cancer via AMPK-independent inhibition of RhoA and Rac1Clinical and Translational Oncology, 2018
- Inhibiting 6-phosphogluconate dehydrogenase reverses doxorubicin resistance in anaplastic thyroid cancer via inhibiting NADPH-dependent metabolic reprogrammingBiochemical and Biophysical Research Communications, 2018
- Inhibiting 6-phosphogluconate dehydrogenase selectively targets breast cancer through AMPK activationClinical and Translational Oncology, 2018
- Advances in the treatment of gastric cancerCurrent Opinion in Gastroenterology, 2017
- Evidence for a direct cross-talk between malic enzyme and the pentose phosphate pathway via structural interactionsJournal of Biological Chemistry, 2017
- Inhibition of 6-phosphogluconate Dehydrogenase Reverses Cisplatin Resistance in Ovarian and Lung CancerFrontiers in Pharmacology, 2017
- Nrf2 Redirects Glucose and Glutamine into Anabolic Pathways in Metabolic ReprogrammingCancer Cell, 2012